Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BINDLEY WESTERN, BERGEN BRUNSWIG DROP PURCHASES FROM SECONDARY SUPPLIERS

Executive Summary

Bindley Western and Bergen Brunswig will no longer rely on secondary sources for pharmaceutical supply, the whslrs. recently announced in separate decisions. Bindley said in a Nov. 11 press release that it halted secondary source purchases in June; Bergen told analysts in late October that it had stopped the purchases. The policy changes were disclosed in the wake of announcements that investigations into allegedly illegal drug diversion practices by whslrs. are continuing. Officials of Bergen Brunswig are reportedly being investigated in the "Pharmoney" investigation based in Atlanta. Bindley Western has appointed a special cmte. comprising its outside board members to review allegations of illegal diversion by the firm and to "formulate recommendations to the board of directors," Bindley announced on Nov. 11. The cmte. members are board secty. Edward Rosenfeld (partner, Indianapolis law firm Rosenfeld Parnell & Shames) and asst. secty. K. Clay Smith (President & CEO, Underwood Machinery Transport, Inc.). On Friday, Nov. 8, federal investigators executed a search warrant at the company's Indianapolis headquarters. The investigators were agents of the Drug Enforcement Administration, the FBI, and the Internal Revenue Service. The search indicates that the Atlanta-based investigation has a companion effort in Indiana. Bindley said the search "was apparently part of an investigation by a federal grand jury in Indianapolis." Bindley also reported that Chairman William Bindley and VP-Treasurer David Swaim are being investigated. The announcement follows a guilty plea by former President Jack Laughner and the sentencing of former VP Stephen Asher ("The Pink Sheet" Nov. 11, p. 6). The Bindley special board cmte. has retained outside counsel to aid in its inquiry, the company noted. As previously announced, another internal investigation by separate outside counsel is ongoing to determine the extent of illegal conduct by former employees and possible involvement by current ones. The law firms involved are Schwab Donnenfeld Bray & Silbert and Wilmer Cutler & Pickering, both of Washington, D.C. Another whslr. announced that rather than avoid secondary sources, it has instituted a program to test pharmaceuticals supplied through the gray market. Med-Sales, a Hollywood, Fla.-based distributor that specializes in secondary-source distribution, announced Nov. 1 that it would test all drugs not obtained direct from the mfr. or an authorized distributor. The program is similar to one recently announced by the drug chain, Revco ("The Pink Sheet" Oct. 7, T&G-3). Med-Sales reportedly sent samples on Nov. 14 from a secondary source shipment containing CooperVision products, to Innotech Labs in Fort Lauderdale for testing.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS009247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel